CVI Program Unit(s):
Lipid / Atherosclerosis / CAD / ACS / Prevention
CVI Research Description:
I am interested in the treatment of atherogenic dyslipidemia, and have a particular interest in the mechanism of action and adverse effects of nicotinic acid.
Dunbar RL, Bouzelmat A, Gipe DA, Pordy R, Sasiela W, Mellis S, Banerjee P : Inhibition Of ANGPTL3 By Evinacumab Reduced Triglycerides (TGs) And LDL-C In Subjects Presenting With Modest Elevations In TGs And/or LDL-C, Recapitulating The Hypolipidemic Effects Of Loss-of-function (LoF) Mutations Of ANGPTL3. Circulation Novemeber 2016 Notes: [Oral Presentation to the American Heart Association Scientific Sessions 2016, New Orleans, LA]
Digenio A*, Dunbar RL*, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM: Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Diabetes Care 39(8): 1408-1415, August 2016 Notes: [Co-first author]
Goldberg RB, Bittner VA, Dunbar RL, Fleg JL, Grunberger G, Guyton JR, Leiter LA, McBride R, Robinson JG, Simmons DL, Wysham C, Xu P, Boden WE: Effects of Extended Release Niacin added to Simvastatin/Ezetemibe on Glucose and Insulin values in AIM HIGH American Journal of Medicine 129(7), July 2016.
Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM: Antisense Mediated Lowering of Plasma Apolipoprotein C‐III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Lipidology 10(3), May 2016 Notes: [Won Second Place in National Abstract Competition and Accepted as Oral Presentation to the 2016 National Lipid Association Scientific Sessions, New Orleans, May 19-22, 2016]
Goel H, Dunbar RL: Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics. Curr Atheroscler Rep 18(4): 17, April 2016.
Reyes-Soffer G, Millar JS, Ngai C, Jumes P, Coromilas E, Asztalos B, Johnson-Levonas AO, Wagner JA, Donovan JS, Karmally W, Ramakrishnan R, Holleran S, Thomas T, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Liu Y, Lassman ME, Gutstein DE, Rader DJ, Ginsberg HN : Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein. Arterioscler Thromb Vasc Biol 36, March 2016.
Dunbar RL, Goel H: Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part I: Alternative Niacin Regimens. Curr Atheroscler Rep 18(2): 11, February 2016 Notes: [As of 8/2016, this paper had an Attention Score of 107 by Altmetric, placing it in the top 5%, a very high score for articles of this age, in part reflecting coverage by 14 news outlets]
Dunbar RL, Nicholls SJ, Maki KC, Roth EM, Orloff DG, Curcio D, Johnson J, Kling D, Davidson MH: Effects of Omega-3 Carboxylic Acids on Lipoprotein Particles and Other Cardiovascular Risk Markers in High-Risk Statin-Treated Patients with Residual Hypertriglyceridemia: A Randomized, Controlled, Double-blind Trial. Lipids Health Dis 14(98): 14, September 2015.
Millar JS, Reyes-Soffer G, Jumes P, Dunbar RL, deGoma EM, Rafeek H, Baer AL, Pollan L, Tohyama J, Liu Y, Johnson-Levonas AO, Wagner JA, Donovan DS, Karmally W, Ramakrishnan R, Holleran S, Obunike J, Lassman ME, Gutstein DE, Ginsberg HN, Rader DJ: Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest 125(6): 2510-2522, June 2015.
deGoma EM, Salavati A, Shinohara RT, Saboury B, Pollan L, Schoen M, Torigian DA, Mohler ER, Dunbar RL, Litt HI, Woo J, Rader DJ, Alavi A, Mehta NN: A Pilot Trial to Examine the Effect of High-Dose Niacin on Arterial Wall Inflammation Using Fluorodeoxyglucose Positron Emission Tomography. Acad Radiol 22(5): 600-609, May 2015.
back to top
Last updated: 12/16/2016
The Trustees of the University of Pennsylvania